These are early-stage clinical data updates with no financial impact. The EIK1001 NSCLC data appear competitive vs historical KEYNOTE benchmarks (ORR 63% vs 43-55% for pembrolizumab+chemo), but cross-trial comparisons are unreliable. Monitor for upcoming Phase 2/3 registrational trial interim analyses in 2H 2026 and any partnership or financing announcements given the company's pre-revenue status.
Price Chart
Executive Summary
Eikon Therapeutics presented updated Phase 2 data for EIK1001 (TLR7/8 agonist) in first-line NSCLC at ASCO 2026, showing a 63.1% ORR and 90.8% DCR across 65 evaluable patients, with median DOR >11 months in the non-squamous cohort. The company also reported initial Phase 1/2 data for EIK1003 (PARP1-selective inhibitor) showing 14.3% ORR as monotherapy and 24.5% ORR in combination with paclitaxel. These are early-stage clinical data readouts with no financial figures or guidance provided.
Key Facts
- EIK1001 Phase 2 TeLuRide-005 trial in first-line stage 4 NSCLC: 63.1% ORR and 90.8% DCR across 65 efficacy-evaluable patients (non-squamous + squamous)
- Non-squamous cohort (n=36): 55.6% ORR, 83.3% DCR, median follow-up 13.6 months, median DOR >11 months
- Squamous cohort (n=29): 72.4% ORR, 100% DCR, median follow-up 8.8 months (data still maturing)
- EIK1003 Phase 1/2 monotherapy (Cohort 1A, n=49 evaluable): 14.3% ORR overall, 26.7% in PARP-naïve patients, median DOR 7.8 months
- EIK1003 + paclitaxel (Cohort 1C, n=53 evaluable): 24.5% ORR, 29.6% in platinum-resistant ovarian cancer, 19.2% in breast cancer
- No financial data, revenue, earnings, or guidance was provided in this filing
Financial Impact
No financial figures reported; clinical data readouts only
Risk Factors
- Pre-revenue biotech with no approved products and significant cash burn
- EIK1001 and EIK1003 are still in Phase 2 and Phase 1/2 respectively; regulatory and clinical failure risk remains high
- No financial guidance or cash runway disclosed in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249725 |
| Document: eikn-ex99_2.htm | 0001193125-26-249725 |
| Document: eikn-ex99_1.htm | 0001193125-26-249725 |
| Document: 0001193125-26-249725-index-headers.html | 0001193125-26-249725 |
| Document: 0001193125-26-249725-index.html | 0001193125-26-249725 |
| Document: 0001193125-26-249725.txt | 0001193125-26-249725 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $7.48 | awaiting T+20 | — | $6.68 (−10.66%) |
Oct 26, 2026 today | Press Release | $7.48 | awaiting T+20 | — | $6.68 (−10.66%) |
Oct 23, 2026 3d ago | 8-K | $8.01 | awaiting T+20 | — | $6.68 (−16.57%) |
Oct 7, 2026 18d ago | SC 13G/A | $7.54 | awaiting T+20 | — | $6.68 (−11.37%) |
Oct 2, 2026 23d ago | SC 13G/A | $7.33 | awaiting T+20 | — | $6.68 (−8.83%) |
Sep 22, 2026 4w ago | Institutional Cluster | $8.98 $8.18 | ▼ −8.91% | ▼ −8.35% | $6.68 (−25.58%) |
Sep 8, 2026 6w ago | Insider Buy | $10.73 $7.54 | ▼ −29.73% | ▼ −31.67% | $6.68 (−37.72%) |
Sep 3, 2026 7w ago | Press Release | $10.96 $8.04 | ▼ −26.64% | ▼ −25.52% | $6.68 (−39.03%) |
Aug 13, 2026 10w ago | 8-K | $11.05 $9.36 | ▼ −15.29% | ▼ −13.30% | $6.68 (−39.52%) |
Jul 20, 2026 14w ago | Press Release | $9.65 $10.47 | ▲ +8.50% | ▲ +4.38% | $6.68 (−30.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers